Probi to acquire Nutraceutix
Swedish probiotics company Probi is to acquire the operations of the US probiotic company Nutraceutix for a preliminary cash purchase price of $105 million.
With this Acquisition, Probi says it will increase its market share in North America more than three-fold, add important new technologies, manufacturing capabilities and customers, and create a strong platform for further acquisitions.
According to Probi, the transaction makes it a top tier integrated probiotics player with dramatically enhanced scale, geographic footprint, capability base and value chain presence, and will more than double Probi¡¦s current size;
The acquisition is said to combine proven, proprietary and patented delivery technology from Nutraceutix with Probi’s well documented strain portfolio, enabling novel, differentiated probiotics products, and to secure access to established, GMP-compliant and versatile manufacturing capabilities with important strategic and financial benefits.
Probi is best known as the maker of LP299V®, the highly appreciated and world’s most researched strain of Lactobacillus plantarum.
